Abstract
Introduction
Asthma remains uncontrolled in many patients receiving inhaled corticosteroid/long-acting β2-agonist (ICS/LABA), suggesting that guideline-recommended escalation to triple therapy is often delayed. We report outcomes in patients with uncontrolled, infrequently exacerbating asthma (understudied in traditional randomized controlled trials) stepping up from ICS/LABA to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) from the PERFORM trial.
Methods
PERFORM, a randomized, open-label, active-controlled, pragmatic trial in symptomatic adults with uncontrolled, infrequently exacerbating asthma, evaluated the effectiveness and safety of FF/UMEC/VI versus usual care ICS/LABA.
Outcomes included trough forced expiratory volume in 1 s (FEV1), asthma control (Asthma Control Questionnaire [ACQ-5/-6/-7]), and achieving clinical remission at Week 52 for the step-up (participants treated with ICS/LABA pre-randomization) and overall population. Safety was assessed throughout the study.Results
![]() |
| Graphical Abstract |
Conclusion
Escalation to FF/UMEC/VI from ICS/LABA improved lung function, asthma control, and clinical remission, with no unexpected safety findings versus usual care ICS/LABA at Weeks 24 and 52, consistent with the overall PERFORM population. Initiation with FF/UMEC/VI may address the unmet need for optimized treatment in patients with uncontrolled, infrequently exacerbating asthma.

No comments:
Post a Comment